fig3
From: Endolymphatic immunotherapy for advanced hepatocellular carcinoma: an update of our experience
Figure 3. Kaplan-Meier survival analysis of patients with advanced hepatocellular carcinoma (endolympahtic immunotherapy vs. control group) (P < 0.0001)
